Best supportive care (BSC) with or without low-dose chemotherapy (chemo) in frail elderly patients with advanced gastroesophageal cancer (aGOAC): The uncertain randomization of the GO2 phase III trial.

Daniel Swinson,Mohan Hingorani,Zuzana Stokes,J. T. Dent,Kamalnayan Guptal,Anirban Chatterjee,Konstantinos Kamposioras,Simon Aird Grumett,Mohammad K. Khan,Helen Marshall,Sharon Ruddock,Christine Allmark,Eszter Katona,Helen Howard,Galina Velikova,Simon Lord,Peter Hall,Matthew T. Seymour

Best supportive care (BSC) with or without low-dose chemotherapy (chemo) in frail elderly patients with advanced gastroesophageal cancer (aGOAC): The uncertain randomization of the GO2 phase III trial.

2019

Daniel Swinson
Mohan Hingorani
Zuzana Stokes
J. T. Dent
Kamalnayan Guptal
Anirban Chatterjee
Konstantinos Kamposioras
Simon Aird Grumett
Mohammad K. Khan
Helen Marshall
Sharon Ruddock
Christine Allmark
Eszter Katona
Helen Howard
Galina Velikova
Simon Lord
Peter Hall
Matthew T. Seymour

4051Background: Before 2000, trials comparing BSC +/- chemo for aGOAC showed overall survival (OS) benefit, but in predominantly fit patients (pts). We have revisited this question in a modern cont...

Keywords:

Gastroesophageal cancer
Physical therapy
Low-dose chemotherapy
Oncology
Randomization
Internal medicine
Medicine
overall survival
frail elderly

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations